BOSTON, MA, June 01, 2017 /24-7PressRelease/
, Inc. will present its digital health technology at the Octane 2017 Technology Innovation & Investor Forum (TIF) June 1-2, 2017. The Ceeable Visual Field Analyzer (CVFA) is a cloud-based digital platform used to detect and diagnose retinal disease, including glaucoma, diabetic retinopathy and macular degeneration. The CVFA will deliver rapid, accurate and low-cost visual testing to patient populations that may not have access to traditional visual testing services.
About Octane TIF
The annual Medical Technology Investor Forum
and the Technology Investor Forum are Orange County's flagship events where multiple industries converge in one place. These events provide vital education and connections to company and personal growth resources and are also indispensable opportunities for early stage companies to gain exposure and to connect with potential investors.
The CVFA can be used in both traditional clinical settings for visual exams and non-traditional settings, from shopping malls to villages. The CVFA is highly mobile and can be accessed from anywhere at any time using a tablet computer and internet connection. This flexibility provides much greater access to patients and caregivers. The Ceeable technology has been used to detect retinal disease on thousands of patients worldwide.
Ceeable, Inc. is a leader in digital mobile health for ophthalmology. The Ceeable Visual Field Analyzer (CVFA) is cloud-based digital platform used to detect and diagnose retinal disease. There are more that 300 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease will reduce healthcare systems costs and help to prevent blindness.